

Edited by
Thomas Ming Swi Chang

**Artificial Kidney,
Artificial Liver,
and Artificial Cells**

Artificial Kidney, Artificial Liver, and Artificial Cells

Edited by

Thomas Ming Swi Chang, M.D., C.M., Ph.D., F.R.C.P.(C)

*Professor of Physiology, Professor of Medicine
Associate, Medical Research Council of Canada
Director, Artificial Organs Research Unit
Faculty of Medicine, McGill University
Montreal, Quebec, Canada*

Plenum Press • New York and London

Library of Congress Cataloging in Publication Data

Main entry under title:

Artificial kidney, artificial liver, and artificial cells.

Includes index.

1. Hemodialysis—Congresses. 2. Artificial kidney—Congresses. 3. Artificial liver—Congresses. I. Chang, Thomas Ming Swi. II. McGill University. Artificial Organs Research Unit. [DNLM: 1. Perfusion—Congresses. 2. Kidney, Artificial—Congresses. 3. Artificial organs—Congresses. 4. Liver—Congresses. 5. Membranes, Artificial—Congresses. 6. Cells—Congresses. 7. Hemodialysis—Congresses. 8. Charcoal—Congresses. WO665 A791 1977]

RC901.7.A7A74

617'.95

77-18738

ISBN 0-306-31125-9

Proceedings of the McGill Artificial Organs Research Unit
International Symposium, McGill University, April 20, 1977

© 1978 Plenum Press, New York
A Division of Plenum Publishing Corporation
227 West 17th Street, New York, N.Y. 10011

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

Preface

There is a rapid increase in interest related to novel approaches in artificial kidneys, artificial liver, and detoxification. Recent research has included the successful clinical applications of the principle of artificial cells for adsorbent hemoperfusion. Since it is 20 years ago at McGill that the first report on "Artificial Cells" was presented, I thought it might be useful to get together a small group of speakers and participants for a day before the ASAIO meeting to discuss some recent advances in the area of the clinical applications of artificial kidney, artificial liver and artificial cells with emphasis on adsorbent hemoperfusion. However, the enthusiastic supports of distinguished speakers, session chairmen and participants were such that the original projection of 100 participants had expanded to a preregistration total of 250, from Australia, Canada, England, France, Germany, Israel, Italy, Japan, The Netherlands, Scotland, Sweden and U.S.A. The program also expanded to include a review section on hemodialysis, dialysate regeneration, hemofiltration, resin hemoperfusion and oxystarch given by their respective originators. The remaining of the symposium emphasizes the status of the art on different encapsulated adsorbent hemoperfusion approaches. I would like to apologize to those who we could not accommodate because of space limitations. It is hoped that this symposium volume may be useful for them and for others who are interested in this area.

Special thanks are due to Ms Joanne Toms for her excellent secretarial assistance for the conference and Mrs. Carol Fautrel for her help in the preparation of this volume; Dr. A. Chawla for organizing the audiovisual aspects; Professor F.C. MacIntosh for his suggestions in organizing the post conference special events; and the McGill Conferences and Special Events especially for organizing the reception and banquets. The members of the Artificial Organs Research Unit who have volunteered their help for this symposium included: M. Berman, Dr. A. Chawla, Dr. E. Chirito, G. Colantoni, Dr. J. Cousineau, Dr. J. Grunwald, C. Hayward, N. Kunterian, C. Lister, P. Nasielski, P. O'Keefe, Dr. B. Reiter, E. Resurreccion and J. Toms. Many thanks are due to my wife, Lancy, for preparing the index for this volume.

The research in this Unit has been enriched by past and present collaborators and members, especially: Dr. P. Barre, Mr. D. Cameron, Dr. J. Campbell, Dr. A. Chawla, Dr. E. Chirito, Dr. S. Chung, Dr. J. Coffey, Dr. C. Cole, Dr. J. Cousineau, Prof. J. Dirks, Mrs. P. Douglas, Dr. H. Duff, Mrs. C. Fautrel, Dr. A. Gonda, Dr. J. Grunwald, Dr. M. Habib, Mrs. C. Hayward, Mrs. M. Hewish, Mr. K. Holeczek, Mrs. L. Johnson, Mrs. N. Kunterian, Mrs. T. Lee-Burns, Mr. B. Lessor, Dr. M. Levy, Mr. C. Lister, Dr. K.S. Lo, Prof. F.C. MacIntosh, Mrs. N. Malave, Miss Celeste Malouf, Prof. S.G. Mason, Dr. M. McGoldrick, Miss M. Migchelsen, Mr. P. Nasielski, Dr. M. Poznansky, Dr. S. Prichard, Miss P. O'Keefe, Dr. B. Reiter, Mrs. E. Resurreccion, Dr. A. Rosenthal, Dr. J. Seely, Dr. E. Siu-Chong, Dr. A. Sniderman, Miss A. Stark, Miss J. Toms, Dr. P. Tung, Mrs. A. Versaza, Dr. B. Watson, and Miss W. Yensen. The support and encouragements in the past or at present in other ways by many others are also gratefully acknowledged, especially, Professor D. Bates, Professor J. Beck, Sir Arnold V.S. Bergen, Professor A. Burton, Professor R.F.P. Cronin, Professor O. Denstedt, Professor S. Freeman, Professor W. Kolff, Professor F.C. MacIntosh, Professor S.G. Mason, Professor G. Malcolm Brown, Professor M. McGregor, Professor R.J. Rossiter, Dr. P. Selkej and many others.

The collaboration of Plenum Publishing Corp. in agreeing to publish this symposium volume is appreciated.

The grant supports for this symposium from the following are gratefully acknowledged: Department of Physiology; McGill University Faculty of Medicine; McGill University Administration; Amicon Corp., U.S.A.; Becton & Dickenson Co., U.S.A.; Extracorporeal Medical Specialties Inc., U.S.A.; Gambro Dialysatoren GmH, Germany; and Warner Lambert Foundation, U.S.A.

The research of the Artificial Organs Research Unit is being supported by the Medical Research Council of Canada.

Thomas Ming Swi Chang

Contents

Address of Welcome	1
L. Yaffe	
INTRODUCTION	3
T. M. S. Chang	
REVIEWS OF HEMODIALYSIS, DIALYSATE REGENERATION, HEMOFILTRATION AND OXYSTARCH	
The Present Status and Perspectives of Hemodialysis	11
W. J. Kolff	
Current Status of Dialysate Regeneration for the Treatment of Chronic Uremia	23
Arthur Gordon, Andrew J. Lewin, Morton H. Maxwell and Martin Roberts	
Devising a Practical Suitcase Hemodialyzer	33
Eli A Friedman, James T. Hutchisson, Robert S. Galonsky and Richard L. Hessert	
Present Status of Hemofiltration	39
Lee W. Henderson	
Oxystarch and Other Polyaldehydes: The Present Status in the Treatment of Uremia	47
Carmelo Giordano and Renato Esposito	
MICROENCAPSULATED ADSORBENT HEMOPERFUSION	
Artificial Cells for Artificial Kidney, Artificial Liver and Detoxification	57
Thomas Ming Swi Chang	

Clinical Experience of Bead-Shaped Charcoal Haemoperfusion in Chronic Renal Failure and Fulminant Hepatic Failure	79
Michio Odaka, Yoichiro Tabata, Hirotada Kobayashi, Yoichi Nomura, Hiromitsu Soma, Hiroyuki Hirasawa and Hiroshi Sato	
Hepatic Assist System Using Bead-Type Charcoal	89
I. Amano, H. Kano, H. Takahira, Y. Yamamoto, K. Itoh, S. Iwatsuki, K. Maeda and K. Ohta	
Extracorporeal Immunoabsorbents for Specific Extraction of Circulating Immune Reactants	99
David S. Terman and George Buffaloe	
Evaluation of Charcoal Hemoperfusion in Uremia	107
James F. Winchester	
Charcoal Hemoperfusion: Georgetown University Hospital Experience	117
Michael C. Gelfand	
Treatment of Fulminant Hepatic Failure by Charcoal Haemoperfusion and Polyacrylonitrile Haemodialysis	125
D. B. A. Silk and Roger Williams	
Use of Activated Adsorbent Haemoperfusion in Acute Intoxication	135
Roy Goulding	
Clinical Experience with Cellulose-Coated Carbon Hemoperfusion	143
A. M. Martin, J. K. Gibbins, A. Oduro, R. Herbert	
Hemoperfusion and Removal of Endogenous Uremic Middle Molecules	153
R. Oulès, H. Asaba, M. Neuhäuser, V. Yahiel, S. Baehrendtz, B. Gunnarsson, J. Bergström and P. Fürst	
Charcoal Hemoperfusion in Mushroom Poisoning: Amanita Phalloides	165
E. Denti, R. Triolo, V. Grivet and A. Ramello	
Biocompatibility Studies of Hemoperfusion Systems for Liver and Kidney Support	173
S. Sideman, E. Hoffer, L. Mor, J. M. Brandes, I. Rousseau, O. Better, D. Ben-Arie and S. Lupovitch	

OTHER ADSORBENT HEMOPERFUSION APPROACHES

- The Use of Membranes and Sorbents for Blood
 Detoxification: Cuprophan Sorbent
 Membranes 185
 P. S. Malchesky and Y. Nose
- Combination of Hemodialysis and Hemoperfusion
 in a Single Hollow-Fiber Unit for
 Treatment of Uremia 193
 L. A. Castro, G. Hampel, R. Gebhardt,
 A. Fateh and H. J. Gurland
- The B-D Hemodetoxifier: Particulate Release
 and Its Significance 199
 John B. Hill and C. Russel Horres
- Fixed-Bed Charcoal Hemoperfusion in the
 Treatment of Drug Overdose and
 Chronic Renal Failure 209
 Benjamin H. Barbour
- Experience with Resin Hemoperfusion 217
 Jerry L. Rosenbaum
- Strathclyde Approach Towards Artificial
 Kidney, Artificial Liver and Detoxification 225
 J. M. Courtney, J. D. S. Gaylor, R. Maini,
 G. B. Park and E. M. Smith

COMMUNICATIONS

- Assessment of Two Rat Models of Fulminant
 Hepatic Failure for Testing Artificial
 Liver Devices 239
 E. Chirito, B. Reiter, C. Lister
 and T. M. S. Chang
- Use of Albumin-Cellulose Nitrate Microencapsulated
 Charcoal Hemoperfusion: In Acute Digoxin
 Toxicity in Dogs 245
 S. Prichard, E. Chirito, A. Sniderman
 and T. M. S. Chang
- Conversion of Urea and Ammonia to Amino Acid
 Using Sequential Enzymatic Reaction
 with Microencapsulated Multi-Enzyme Systems 249
 J. Cousineau and T. M. S. Chang

Microencapsulated Charcoal Hemoperfusion for Galactosemia	255
P. Nasielski and T. M. S. Chang	
The Filtration of Plasma from Whole Blood: A Novel Approach to Clinical Detoxification	259
Franco Castino, Leonard I. Friedman, Barry A. Solomon, Clark K. Colton and Michael J. Lysaght	
Ionsiv F-80 and Ionsiv W-85: Molecular Sieve Zeolite NH_4^+ Ion Exchangers for Removal of Urea Nitrogen	267
John D. Sherman	
PANEL AND GENERAL DISCUSSIONS	
Chronic Renal Failure and Future Approaches	277
Benjamin T. Burton	
Status of Artificial Liver Support: 1977	281
Paul D. Berk	
Treatment of Acute Intoxication	293
George Schreiner	
Interrelation of Hemoperfusion, Plasma Clearance and Half Life	297
John F. Maher	
General Discussion	301
Thomas Ming Swi Chang	
Invited Speakers, Session Chairmen and Organizing Committee	305
Index	309

ADDRESS OF WELCOME

L. Yaffe

Vice Principal, McGill University

Montreal, Quebec, Canada

I am very happy to welcome you here on behalf of Principal Bell and the Board of Governors. McGill is extremely proud of its Faculty of Medicine. McGill also prides itself on the fact that it has a tradition of excellence. In these days of egalitarianism, democratic society, etc., it is virtually considered elitist to be excellent, but I think your presence here today at a conference like this, shows that you yourselves are committed to this very same principle of excellence. Without this, scholarship in any discipline, especially in the sciences, could never survive. I want to congratulate Professor Chang on attracting such a distinguished group of people but I also want to congratulate the audience because when I took a look at the program and the length and content of the program, I recognized that it would take a certain kind of stamina to be able to endure this. I would be interested to see what you look like at about 5:30 or 6:00 this afternoon. I know you did not come here to hear me. You have a very long and a very good program. May I wish you a great deal of success in this conference. Thank you very much.

INTRODUCTION

T.M.S. Chang

Artificial Organs Research Unit
McIntyre Medical Sciences Building
McGill University
Montreal, Quebec, Canada

HEMODIALYSIS

Introduction

In 1913, Abel et. al. demonstrated that using the principle of hemodialysis, they were able to remove diffusible substances from the circulating blood of rabbits. This principle of hemodialysis remained as an experimental curiosity until about 30 years later when Kolff successfully developed a hemodialyser that can be used effectively for the treatment of patients with renal failure (Kolff, 1944, 1947, also in this volume). However, long-term maintenance of patients was associated with the difficulty of repeated accesses to the blood vessels. It took another 15 years for Scribner's group (Quinton et. al., 1961) to develop the arteriovenous shunt which makes it possible for long-term intermittent accesses to blood vessels of patients. Since that time the use of hemodialysis for the long-term maintenance of patients with chronic renal failure has become an established procedure. At present there are many patients who have been maintained alive for more than 10 years by long-term hemodialysis. The standard hemodialysers are based on the principle of, (1) dialysis for the removal of diffusible molecules and (2) ultrafiltration for the removal of water and sodium chloride (Fig. 1). Although hemodialysis has been conclusively demonstrated to be effective for the maintenance of chronic renal failure patients there are a number of problems related to its use. The major problems are related to the complexity and size of the machine and the cost and time required for treatment (6-12 hours three times a week).




Figure 1

At present the exact type of toxic molecules that has to be removed and the essential molecules which should not be removed still have not been established. Hemodialysis though useful in treating some form of drug intoxication (Maher and Schreiner, 1969) can be further improved. The standard hemodialysers have not been demonstrated to be effective for treating liver failure. A large amount of research has therefore been carried out in the areas of artificial kidney, artificial liver and detoxifiers. Most of the developments have been related to the improvements, modifications and extensions of the principle of hemodialysis. Thus, the earlier developments involved the use of different membrane configurations in the form of coils, plates, and capillaries. This has resulted in substantial improvements in the membrane component of the hemodialysis machine. A great deal of advance has also been made in the monitoring system. The development of the internal AV fistula (Brescia et. al., 1966) has overcome a number of the problems related to the external A-V shunts. The single needle approach (Kopp et. al., 1972) has lessened problems related to needle puncture in internal AV fistula.

Dialysate Regeneration

One of the major problems of standard hemodialysis machine is




Figure 2

the dialysate required for removing uremic metabolites (Fig. 1). Approximately 300 litres of fluid is required for each treatment. This means that about 900 litres per week is required for the 3 times a week treatment. In addition to the very high cost of dialysate, there are other problems related to possible trace element being absorbed by the patients from this large volume of fluid. The principle of dialysate regeneration is a successful attempt to decrease the dialysate volume required by using sorbents in the dialysate fluid compartment to remove the uremic metabolites (Fig. 2) (Gordon et. al., 1969, also in this volume). This principle has been used for the construction of a "wearable artificial kidney" (Kolff, in this volume).

Middle Molecules

The proposal that uremic toxins are molecules in the middle molecular weight range (Babb et. al., 1972) has led to modifications of hemodialysers. Thus the total membrane area has been increased to facilitate the removal of these "middle molecules". Membranes with high permeability to middle molecules (e.g. Rhone-Poulone) have also been developed.




Figure 3

Hemofiltration

Another approach related to middle molecules is the use of the principle of hemofiltration whereby instead of using a combination of dialysis and ultrafiltration (Fig. 1) only ultrafiltration is used (Fig. 3) (Henderson et al., 1967; Henderson, in this volume). Hemofiltration (Fig. 3) is based on the principle that, unlike dialysis, permeant molecules of different molecular weight can move across a membrane at the same rate in ultrafiltration. This way, middle molecules can be removed as effectively as the smaller molecules. The ultrafiltrate removed has to be replaced very accurately with diluting solution in order not to deplete or overload the fluid volume of the patients.

Reviews

Some of these recent novel approaches related to new extension and modifications of hemodialysis will be reviewed by their originators.

ADSORBENTS

Many adsorbents like activated charcoal, oxystarch, ion-exchange resins, and others have been used. Activated charcoal is used in the dialysate regeneration system described above. It has also been used for hemoperfusion (Yatzidis, 1964) however, complications related to embolism and platelet depletion has prevented its clinical use as free granules for hemoperfusion. The use of oxystarch (Giordano, in this volume) and amberlite (Rosenbaum, in this volume) will be reviewed by their original proponents in this volume.

ARTIFICIAL CELLS

Introduction

With the thought that most of the novel approaches in artificial kidney have been extensions and modifications of hemodialysis; and also with the thought that perhaps completely different approaches may also contribute to the further development of artificial kidney, artificial liver and detoxification, a new area of research was started here. This involved investigations into the possible uses of artificial cells (microencapsulation) as the basis for the construction of artificial liver, artificial kidney and detoxifier (Fig.4) (Chang, 1964, 1966, 1972). The ultrathin membrane and the large surface to volume relationship of artificial cells is such that a very small volume of suspension allows for extremely high transport rates of metabolites. Studies carried out to use enzyme systems in the artificial cells for the removal and conversion of metabolites have recently been reviewed in more detail elsewhere (Chang, 1977).




Figure 4

Microencapsulated Adsorbents

This volume reviews in some detail the use of artificial cells or other extensions to encapsulate adsorbents for clinical applications as artificial kidneys, artificial livers, and detoxifiers. Most centers working in this area at present have contributed to this volume.

REFERENCES

- Abel, J.J., Rowntree, L.G. and Turner, B.B. (1913). Trans. Assoc. Amer. Physicians, 28, 51.
- Babb, A.L., Farrell, D.A., Uvelli, D.A. and Scribner, B.H. (1972). Trans. Amer. Soc. Artif. Intern. Organs, 13, 98.
- Brescia, M.J., Crimino, J.E., Appel, K. and Hurwith, B.J. (1966). New England J. Med., 275, 1089.
- Chang, T.M.S. (1964). Science, 146, 524.
- Chang, T.M.S. (1966). Trans. Amer. Soc. Artif. Intern. Organs, 12, 13.
- Chang, T.M.S. (1972). Artificial Cells, Charles C. Thomas, Publisher, Springfield, Illinois.
- Chang, T.M.S. (1977). Biomedical Application of Immobilized Enzymes and Proteins, Plenum Publishing Corp., New York. Volumes 1 & 2.
- Giordano, C. In this volume.
- Gordon, A., Greenbaum, M.A., Marantz, L.B., McArthur, M.H. and Maxwell, M.H. (1969). Trans. Amer. Soc. Artif. Intern. Organs, 15, 347.
- Gordon, A. In this volume.
- Henderson, L.W., Besarab, A., Michaels, A.S. and Blume, L.W. (1967). Trans. Amer. Soc. Artif. Intern. Organs, 13, 216.
- Henderson, L.W. In this volume.
- Kolff, W.J. (1944). Acta. Med. Scand., 117, 121.
- Kolff, W.J. (1947). "New Ways of Treating Uremia", J. & A. Churchill Ltd., London, U.K.
- Kopp, K.F., Gutch, C.F. and Kolff, W.J. (1972). Trans. Amer. Soc. Artif. Intern. Organs, 18, 75.
- Maher, J.E. and Schreiner, G.E. (1969). Trans. Amer. Soc. Artif. Intern. Organs, 15, 461.
- Quinton, W.E., Dillard, D.H., Cole, J.J. and Scribner, B.H. (1961). Trans. Amer. Soc. Artif. Intern. Organs, 7, 60.
- Rosenbaum, J. In this volume.
- Yatzidis, D. (1964). Pro. Eur. Dial. Transpl. Assoc., 1, 83.